NCT03383965

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

A Clinical Study of CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Immune Cell, Inc. · Industry
• Sex: All
• Age: 2 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive. In this study, a newly CD30 targeted CART therapy ICAR30 is designed to specifically kill those CD30 expressing malignancies including Hodgkin's lymphoma and CD30+ anaplastic large cell lymphoma. The subjects will receive several doses of autologous ICAR30 T cells infusion and then the safety, treating effects and lasting period of these cells in vivo will be evaluated.

Conditions

• Hodgkin Lymphoma
• Anaplastic Large Cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	ICAR30 T cells	T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.

Timeline

• Start date: 2017-03-01
• Primary completion: 2020-12-31
• Completion: 2025-12-31
• First posted: 2017-12-27
• Last updated: 2017-12-27

Locations

1 site across 1 country: China